BioNTech plans to return €2bn to shareholders through share buybacks and a special dividend following the commercial success of its Covid-19 vaccine, the company said on Wednesday.
BioNTech週三宣佈擬通過股票回購和特別股息向股東返還20億歐元，先前該公司的新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）疫苗取得商業成功。
您已閱讀12%（259字），剩餘88%（1963字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。